Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
about
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Emerging biological therapies for the treatment of myelodysplastic syndromes.Panobinostat for the treatment of acute myelogenous leukemia.Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Management of myelofibrosis: JAK inhibition and beyond.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.
P2860
Q30235355-54BCDFA3-BC84-4B70-A761-9F5CD8F25A63Q33437309-85F13FBD-82A0-448F-98E0-4CF0B505ED96Q38651923-408146CF-D601-4315-9C73-103AEF31D137Q38664735-E8A1C581-DF8F-4EAA-A2C4-8117F4775982Q38834981-0783812E-2E13-4C80-A7FC-E38CE31420B2Q38835113-68DC3784-12FB-4CFF-8801-2841C63471FBQ38967853-07C600E0-E132-4AED-853C-018B33F0EBF5Q39232415-AA6D67A0-AA46-487C-958F-87BC90598126Q39413114-DD5C6740-16B5-49E3-8807-338223D835E2Q41573313-595B0F60-2FEB-400F-A153-39F5E787A658Q41924355-3CA4D37E-5BB7-4940-97A9-51306ECC760FQ47172395-7D1B8065-EBAB-420A-8958-5068C6990260Q55515597-FA78B035-C079-4295-A6EF-CD2ACF6EFAFC
P2860
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Lost in translation? Ten years ...... and myelodysplastic syndromes.
@en
type
label
Lost in translation? Ten years ...... and myelodysplastic syndromes.
@en
prefLabel
Lost in translation? Ten years ...... and myelodysplastic syndromes.
@en
P2093
P2860
P1476
Lost in translation? Ten years ...... and myelodysplastic syndromes.
@en
P2093
Maximilian Stahl
Norbert Vey
Steven D Gore
P2860
P304
P356
10.1517/13543784.2016.1146251
P407
P577
2016-01-25T00:00:00Z